NVM realises Pivotal investment

UK small cap investor NVM Private Equity has sold Pivotal Laboratories, a provider of laboratory support for clinical trials, in an exit which has generated a 2.2x return and an IRR of 27%.

York-based Pivotal has been acquired by ACM, a North American clinical laboratory. The sale marks the end of an investment which began when NVM backed a management buyout in August 2005.

The business specialises in analytical services for pharmaceutical and biotech companies involved in human testing.